| P2093 | author name string | W Walther | |
| | U Stein | |
| P2860 | cites work | Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus | Q24523073 |
| | A family of retroviruses that utilize related phosphate transporters for cell entry | Q24645533 |
| | Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors | Q24683259 |
| | Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis | Q24684374 |
| | Increase of retroviral infection in vitro by the binding of antiretroviral antibodies | Q27486825 |
| | Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC) | Q28145671 |
| | Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system | Q28286009 |
| | A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia | Q28291035 |
| | HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase | Q28291170 |
| | In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector | Q29547503 |
| | Production of high-titer helper-free retroviruses by transient transfection | Q29547802 |
| | Characteristics of a human cell line transformed by DNA from human adenovirus type 5 | Q29547863 |
| | Tissue-specific targeting of retroviral vectors through ligand-receptor interactions | Q41428152 |
| | Viral vectors for gene therapy of hematopoietic cells | Q41473032 |
| | The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. | Q41517544 |
| | Human immunodeficiency virus infection of cells arrested in the cell cycle | Q41531689 |
| | Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. | Q41548684 |
| | Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir | Q41576545 |
| | Efficient incorporation of human CD4 protein into avian leukosis virus particles | Q41710940 |
| | Gaucher's disease: studies of gene transfer to haematopoietic cells | Q41719206 |
| | Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells | Q41892079 |
| | Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells | Q41904037 |
| | Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes | Q41994305 |
| | Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 |
| | Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. | Q42483788 |
| | Sindbis virus: an efficient, broad host range vector for gene expression in animal cells | Q42991441 |
| | Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase | Q43185222 |
| | Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. | Q43866864 |
| | Interaction of vesicular stomatitis virus-G pseudotyped retrovirus with CD34+ and CD34+ CD38- hematopoietic progenitor cells | Q44102494 |
| | Towards gene therapy of Hurler syndrome | Q44296148 |
| | Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture | Q44460699 |
| | Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). | Q44544229 |
| | Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats | Q44544234 |
| | Epidemiology of adenovirus-associated virus infection in a nursery population | Q44631695 |
| | Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin | Q44803404 |
| | In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant | Q44859779 |
| | Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression | Q44939592 |
| | Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice | Q45175987 |
| | Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors | Q45299117 |
| | Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates | Q45753061 |
| | Recombinant adeno-associated virus for muscle directed gene therapy | Q45764433 |
| | Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model | Q45765329 |
| | A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. | Q45769906 |
| | Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. | Q45782481 |
| | First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen | Q45785005 |
| | Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 |
| | Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors | Q45862326 |
| | Retroviral vectors displaying functional antibody fragments | Q40405683 |
| | Pseudotyped retroviral vectors for studies of human gene therapy | Q40429875 |
| | The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos | Q40642168 |
| | Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer | Q40928916 |
| | Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. | Q40931797 |
| | Recombinant adeno-associated virus (rAAV) vectors for somatic gene therapy: recent advances and potential clinical applications | Q40936864 |
| | Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors | Q40988268 |
| | High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus | Q40992577 |
| | Inducible expression of p21WAF-1/CIP-1/SDI-1 from a promoter conversion retroviral vector | Q41071646 |
| | Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting | Q41139949 |
| | Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis | Q41226051 |
| | Targeting retrovirus entry | Q41239958 |
| | FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer | Q41275978 |
| | Retroviral targeted delivery | Q41295238 |
| | Correlation between complementation group for immortality and the cellular distribution of mortalin. | Q41391947 |
| | Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo | Q29616612 |
| | A new generation of animal cell expression vectors based on the Semliki Forest virus replicon | Q30014839 |
| | Expanded-capacity adenoviral vectors--the helper-dependent vectors | Q33544035 |
| | Chimeric viral vectors--the best of both worlds? | Q33544037 |
| | Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors | Q33783728 |
| | Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector | Q33856071 |
| | Ligand-directed retroviral targeting of human breast cancer cells | Q33868131 |
| | Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors. | Q33880416 |
| | Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding | Q33886233 |
| | In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses | Q33932227 |
| | Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination | Q33938668 |
| | Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery | Q34066344 |
| | Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene | Q34073641 |
| | Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 |
| | A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine le | Q34321338 |
| | Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts | Q34352418 |
| | Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction | Q34354588 |
| | An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 |
| | Applications of pox virus vectors to vaccination: an update | Q34403246 |
| | The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. | Q34408549 |
| | Human gene therapy | Q34419327 |
| | Transcriptional Silencing of Retroviral Vectors. | Q34450066 |
| | Adeno-associated virus vectors can be efficiently produced without helper virus | Q34479933 |
| | Comparison of promoter suppression in avian and murine retrovirus vectors | Q35058620 |
| | Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy | Q35064037 |
| | Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells | Q35604467 |
| | A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes | Q35796872 |
| | Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. | Q35831286 |
| | Retroviral retargeting by envelopes expressing an N-terminal binding domain. | Q35848344 |
| | High-titer packaging cells producing recombinant retroviruses resistant to human serum | Q35851698 |
| | Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes | Q35858284 |
| | Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. | Q35860180 |
| | A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. | Q35861566 |
| | cis-acting elements that mediate the negative regulation of Moloney murine leukemia virus in mouse early embryos | Q35866586 |
| | A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group | Q45862712 |
| | Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease | Q45866523 |
| | A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis | Q45866575 |
| | T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. | Q45866838 |
| | Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung | Q45867192 |
| | Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo | Q45868140 |
| | Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. | Q45868776 |
| | Stage I clinical trial of gene therapy for hemophilia B. | Q45872616 |
| | Cytokine mobilization of peripheral blood stem cells in patients with Gaucher disease with a view to gene therapy. | Q45875786 |
| | The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker | Q45876126 |
| | Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors | Q45876696 |
| | Gene transfer into the mouse retina mediated by an adeno-associated viral vector | Q45877692 |
| | Direct gene transfer to the liver with herpes simplex virus type 1 vectors: transient production of physiologically relevant levels of circulating factor IX | Q45879558 |
| | Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. | Q45879817 |
| | Episomal expression of wild-type CFTR corrects cAMP-dependent chloride transport in respiratory epithelial cells | Q45881865 |
| | Functional correction of Fanconi anemia group A hematopoietic cells by retroviral gene transfer | Q45883938 |
| | Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms | Q45884636 |
| | A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons | Q46135759 |
| | ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents | Q46343726 |
| | Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver | Q48004746 |
| | A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors | Q48762505 |
| | Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter. | Q50798159 |
| | ONYX-015: clinical data are encouraging | Q56898602 |
| | Retrovirus-Mediated Transfer of the cDNA for Human Glucocerebrosidase into Peripheral Blood Repopulating Cells of Patients with Gaucher's Disease. University of Wisconsin, Madison, Wisconsin | Q60160336 |
| | Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III | Q64382267 |
| | Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial | Q64382613 |
| | Adenoviruses: group name proposed for new respiratory-tract viruses | Q64386110 |
| | Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma | Q67987475 |
| | Autologous bone marrow transplant for children with AML in first complete remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse | Q68000944 |
| | Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor | Q68094544 |
| | A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse | Q68266879 |
| | Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous ma | Q68274666 |
| | A gene delivery system activatable by disease-associated matrix metalloproteinases | Q73254121 |
| | A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis | Q74530902 |
| | Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus | Q77292224 |
| | Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. | Q35868577 |
| | Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. | Q35871002 |
| | Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. | Q35875806 |
| | Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. | Q35881081 |
| | Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. | Q35891440 |
| | Stability without a centromere | Q36185004 |
| | Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood | Q36363237 |
| | Sustained correction of bleeding disorder in hemophilia B mice by gene therapy | Q36454880 |
| | Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells | Q36506251 |
| | Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors | Q36622965 |
| | Characterization of a bicistronic retroviral vector composed of the swine vesicular disease virus internal ribosome entry site | Q36686421 |
| | Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection | Q36720691 |
| | Human artificial episomal chromosomes for cloning large DNA fragments in human cells | Q36729587 |
| | Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors | Q36734619 |
| | Transient dominant selection of recombinant vaccinia viruses. | Q36808769 |
| | A safe packaging line for gene transfer: separating viral genes on two different plasmids | Q36865708 |
| | Development of retrovirus vectors useful for expressing genes in cultured murine embryonal cells and hematopoietic cells in vivo | Q36873087 |
| | Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. | Q37181003 |
| | T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. | Q37182935 |
| | A deletion mutant in the human cytomegalovirus gene encoding IE1(491aa) is replication defective due to a failure in autoregulation | Q37248409 |
| | Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety | Q37249251 |
| | Negative-strand RNA viruses: genetic engineering and applications | Q37249720 |
| | Use of virion DNA as a cloning vector for the construction of mutant and recombinant herpesviruses | Q37251335 |
| | Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector | Q37271693 |
| | Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector | Q37319132 |
| | A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase | Q37551841 |
| | Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. | Q38359595 |
| | Replication of plasmids derived from bovine papilloma virus type 1 and Epstein-Barr virus in cells in culture | Q39160064 |
| | Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. | Q39577503 |
| | Receptor-binding domain of murine leukemia virus envelope glycoproteins. | Q39868615 |
| | Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses | Q39879953 |
| | Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. | Q40042967 |
| | Packaging system for rapid production of murine leukemia virus vectors with variable tropism | Q40067097 |
| | Construction of retroviral vectors for targeted delivery and expression of therapeutic genes | Q40368888 |
| | A transient three-plasmid expression system for the production of high titer retroviral vectors | Q40393091 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vector-borne disease | Q2083837 |
| P304 | page(s) | 249-71 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Viral vectors for gene transfer: a review of their use in the treatment of human diseases | |
| P478 | volume | 60 | |